Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

11 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06862869 2026-04-06

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Recruiting

800 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04302025 2026-04-03

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

99 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06765109 2026-03-24

ALKAZAR

Phase 3 Recruiting

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

200 enrolled

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

303 enrolled 31 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02314481 2025-05-23

DARWINII

Phase 2 Active not recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

247 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06709274 2024-11-29

MOTION-NSCLC

Phase NA Not yet recruiting

342 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04351334 2024-09-19

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Completed

161 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

Phase 2 Active not recruiting

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06339554 2024-04-01

TOSS-ALK

Completed

98 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

154 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03271554 2022-11-18

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Completed

355 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1/2 Terminated

5 enrolled 8 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02013219 2020-04-21

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

52 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03155009 2020-02-10

ATALK

Phase 2 Completed

44 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3 Completed

119 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01801111 2018-11-02

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Phase 1/2 Completed

138 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01871805 2018-08-21

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

134 enrolled 35 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02271139 2017-03-09

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

No longer available

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Alectinib Pharmacokinetic in Patients With NSCLC

HORIZON 2

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

ALKAZAR

B-FAST

HORIZON 1

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

ALEX

DARWINII

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

ALERT-lung

DELINOR

ORCHARD

MOTION-NSCLC

PIKACHU

ATPase

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

ALNEO

EROS

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

ADAPT ALEC

TOSS-ALK

BLISS

ROME

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

ATALK

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy